1-4 of 4
Dirk Pleimes, MD
Close
Sort by
Journal Articles

Effects of a Novel Orally Bioavailable Small Molecule (Imidazolyl Ethanamide Pentandioic Acid) on Acute Radiation Syndrome

Dirk Pleimes, MD, Vivienne Bunker, Michael Meyer, Maciej Czajkowski
Journal: Blood
Blood (2018) 132 (Supplement 1): 5089.
https://doi.org/10.1182/blood-2018-99-114490
Published: 2018
Journal Articles

Induced Myelosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups

Dirk Pleimes, MD, Volker Möbus, Frank Mayer, Marcus Schmidt, Corinna Asang, Kathrin Flunkert, Gerd Mikus
Journal: Blood
Blood (2018) 132 (Supplement 1): 5106.
https://doi.org/10.1182/blood-2018-99-114220
Published: 2018
Journal Articles

Chemotherapy Efficacy on Human Breast Cancer Xenograft in Mice Remains Effective in Combination with Myelo001, a Novel Orally Bioavailable Small Molecule to Treat Myelosuppression

Patrik PK Brehm, MSc, Neeta Donnimath, MSc, Dirk Pleimes, MD
Journal: Blood
Blood (2016) 128 (22): 5068.
https://doi.org/10.1182/blood.V128.22.5068.5068
Published: 2016
Journal Articles

Effect of IEPA, a Novel Orally Bioavailable Small Molecule, on Chemotherapy-Induced Myelosuppression

Dirk Pleimes, MD, Susanne Flechsig, PhD, Michael Meyer, PhD
Journal: Blood
Blood (2014) 124 (21): 4355.
https://doi.org/10.1182/blood.V124.21.4355.4355
Published: 2014